Supernus Sues Actavis for Infringement of Trokendi XR(R)

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Supernus Sues Actavis for Infringement of Trokendi XR(R) Patents

ROCKVILLE, Md., Oct. 2, 2014 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN ) announced that earlier today it sued generic drug makers Actavis plc, Actavis, Inc., Actavis Laboratories FL, Inc., Actavis Pharma, Inc., Watson Laboratories, Inc., and Anda, Inc. (collectively "Actavis") for infringement of three patents covering its antiepileptic drug Trokendi XR®. Supernus' United States Patents Nos. 8,298,576, 8,298,580, and 8,663,683 cover once-a-day topiramate formulations and methods of treating seizures using those formulations. Patent protection for Trokendi XR® does not expire until 2029.

The Complaint—filed in the U.S. District Court for the District of New Jersey—alleges that Actavis infringed Supernus' Trokendi XR® patents by submitting to the Food and Drug Administration ("FDA") an Abbreviated New Drug Application ("ANDA") seeking to market a generic version of Trokendi XR® prior to the expiration of Supernus' patents. Filing its Complaint within 45 days of receiving Actavis' Paragraph IV certification notice entitles Supernus to an automatic stay preventing the FDA from approving Actavis' ANDA for 30 months.

Supernus President and CEO Jack Khattar confirmed that "Supernus intends to vigorously enforce its patent rights."

Supernus is represented by attorneys from Frommer Lawrence and Haug LLP and its corporate counsel, Saul Ewing LLP.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR® (extended-release topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.

Forward Looking Statements

This press release contains forward-looking statements regarding the Company's ability to defend and enforce its intellectual property rights covering Trokendi XR®. Actual results may differ materially from those in these forward-looking statements as a result of various factors, including, but not limited to, the ability of Supernus to finance potential litigation and to prevail in any such proceeding to successfully defend its intellectual property rights. For a further description of these and other risks facing the Company, please see the risk factors described in the Company's Annual Report Form 10-K that was filed with the United States Securities and Exchange Commission on March 21, 2014 under the caption "Risk Factors" and the updates to these risk factors in the Company's quarterly report form 10-Q filed with the commission on August 12, 2014. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise these statements, except as may be required by law.

Jack A. Khattar, President and CEO Gregory S. Patrick, Vice President and CFO Supernus Pharmaceuticals, Inc. 301-838-2591 or INVESTOR CONTACT: COCKRELL GROUP 877-889-1972 cockrellgroup.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ortho Molecular and HANS: Streamlining Functional Medicine

Updated Category News Views 130

Functional Medicine Gets a Tech Boost The world of functional medicine just got a major shot in the arm, courtesy of an intriguing alliance between Ortho Molecular Products and HANS.FM. First of all, let's address the elephant in the room: clinicians in this field aren't exactly on a coffee break. They’re buried under mountains of paperwork, often spending hours just...

Continue Reading
CURE Intl and Thoughtworks Step Into Digital Era

Updated Category News Views 117

Pushing Paper Out, Digitizing In In a world where tech is king, why were hospitals—crucial, life-saving institutions—still bogged down by dusty folders and ink smudges? Well, not anymore for CURE International, not with Thoughtworks stepping up to the plate. This ain't just swapping paper for pixels; it's a lifeline for kids getting world-class surgical care without...

Continue Reading
Jinko Solar Joins B20 Summit: Energy Forefront Focus

Updated Category News Views 105

Jinko Solar's Invitation to the B20 Summit Never a dull moment in the solar space, especially when Jinko Solar, a big shot in clean energy, jumps into the spotlight at the B20 Summit in the U.S. Awash with high-profile discussions, Jinko's not just chatting—it's the only photovoltaic firm strutting its stuff in D.C. with gutsy calls for energy reform. Key Takeaways from...

Continue Reading
Jubilant Eyes MPN Breakthrough with JBI-802 Data at ASH

Updated Category News Views 47

Presenting the Case for JBI-802 From the bustling circus of drug development, here comes Jubilant Therapeutics, strutting their stuff with JBI-802, a dual inhibitor designed to tackle myeloproliferative neoplasms (MPNs) with a one-two punch. Now, they're set to drop some spicy deets at the 68th ASH Annual Meeting in New Orleans this December. So what's the fuss about?...

Continue Reading
Agilyx's Q3 Update: GreenDot Shines Amid Mixed Results

Updated Category News Views 130

Peeking into Agilyx's Financial Odyssey Just as I sip my morning coffee pondering the highs and lows of the market, here comes Agilyx ASA splashing some liquidity on the scene. The Q3 report paints the company in various shades—from solid greens to hesitant reds. Nothing like the thrill of untangling mixed results over a quiet day, huh? GreenDot's Climb to Profitability...

Continue Reading
Inflatable Wonders Turn Christmas into a Hoot at Lowe's

Updated Category News Views 27

Inflatables Bringing the Cheer (and Laughs) Well, it's that season again—where decorations either have us grumbling at the electric bill or chuckling at the lawn art. Lowe's has teamed up with Gemmy to serve a heaping platter of holiday giggles this year. They've rolled out a quirky lineup of inflatables that go from shivering Highland cows to dinosaurs and elves....

Continue Reading
LG Innotek Scores Hat Trick with CES Innovation Wins

Updated Category News Views 86

LG Innotek's Lighting Triumph Here we go again, LG Innotek just snagged their third CES Innovation Award in a row, this time for their cutting-edge vehicle lighting module, Nexlide C+. It's one for the books—breaking into the 2027 CES spotlight with innovative tech that not only grabs the eyes but could also steal the hearts of investors willing to bet on the future of...

Continue Reading
RF MEDICAL Expands into Europe with New CE Certification

Updated Category News Views 62

RF MEDICAL Secures CE Marking for Mi-BLATOR™ Just when you think the European medical device market's hit its saturation point, RF MEDICAL decides to kick the door open with their Mi-BLATOR™ microwave ablation system. This ain't just another plastic gadget, folks; it's got that shiny new CE marking under the European Union's Medical Device Regulation (MDR). Now, what...

Continue Reading
BD Sets Stage for Investor Day in December 2026

Updated Category News Views 9

BD's Investor Day: A Peek into the Future Say what you will about investor meets, but BD (Becton, Dickinson and Company) throwing its shindig on December 10, 2026, could be a highlight on the calendar if you're eyeing the medical technology sector. Scheduled in New York, this event is gearing up to be a canvas for BD's higher-ups to sketch out their roadmap. If you’re...

Continue Reading
Centrus Energy Welcomes Nuclear Veteran to Leadership

Updated Category News Views 14

Navigating a New Era at Centrus When you hear about seasoned veterans stepping up to the plate in the energy sector, it's time to perk up your ears. Centrus Energy (NYSE:LEU), a big player in nuclear fuel, just added Kevin Graney to their Board of Directors. This isn't your run-of-the-mill appointment; it packs nearly three decades of nuclear tech and national security...

Continue Reading

Top 5 Most Recently Viewed Articles

Oracle's Stellar Growth: A Deep Dive into Recent Surge

Updated Category News Views 389

Oracle Shares Experience Remarkable Growth in Trading In exciting news, Oracle Corp. (NYSE: ORCL) is making waves in the stock market, as its shares surge in value. This Texas-based enterprise software giant saw a significant increase, recording a 35.95% rise during the regular trading session. Following this impressive performance, a further increase of 1.42% in...

Continue Reading
Creative Global Technology Holdings Limited Reports 2024 Success

Updated Category News Views 329

Financial Overview of Creative Global Technology Holdings Limited Creative Global Technology Holdings Limited (NASDAQ: CGTL), renowned for sourcing and reselling recycled consumer electronics, has shared its impressive financial results for the fiscal year ending 2024. Despite a decrease in overall revenue, the company has achieved significant growth in gross profit and...

Continue Reading
Exciting Financial Insights Ahead for Gilat Satellite Networks

Updated Category News Views 173

Gilat Satellite Networks Set to Announce Financial Results Gilat Satellite Networks Ltd. (Nasdaq: GILT, TASE: GILT), recognized globally as a frontrunner in satellite networking technology, is gearing up to announce its fourth quarter and full year 2024 financial results. The announcement is set for an engaging conference call on an upcoming Wednesday. Details of the...

Continue Reading
PKGD Group's Agave Spirits Surge 56% in 2026 Growth'

Updated Category News Views 84

PKGD Group's Impressive Growth Story Sometimes you read a report and it genuinely knocks the wind out of you—not because it’s unusual, but because it’s rare to see such robust numbers in a market that ain't exactly all sunshine and rainbows. PKGD Group, the brain behind some damn fine agave spirits, decided to take no prisoners this year, reporting a jaw-dropping...

Continue Reading
Analysts Raise Expectations for Booking Holdings After Earnings

Updated Category News Views 204

Booking Holdings Surprises Analysts with Earnings Report Booking Holdings (NASDAQ: BKNG) recently released its quarterly earnings, exceeding expectations and impressing industry analysts. With a strong report showcasing earnings of $99.50 per share, the company surpassed analysts' forecast of $95.25 per share significantly. Sales figures also bolstered investor...

Continue Reading